ETP Nanomedicine

What ETP Nanomedicine does

ETP Nanomedicine is a Paris-based, privately held entity founded in 2014 that, per its listed description, addresses the application of nanotechnology to achieve breakthroughs in healthcare. The organization is registered as a for-profit company with an employee count of 1-10, suggesting an extremely lean operating structure, and maintains a web presence at etp-nanomedicine.eu.

The available data does not disclose any products, services, technology stack, pricing model, go-to-market motion, customer segments, funding rounds, management team, partnerships, or revenue. The company website, at the time of capture, returned only a loading/verification page with no substantive content on technology, products, or business model. The naming convention ("ETP"), Paris domicile, and for-profit-but-minimal structure are consistent with the European Technology Platform on Nanomedicine, an EU-coordinated industry-academia framework, and one source commentary explicitly notes that the entity may function as such a framework rather than a traditional commercial enterprise. This characterization is not confirmed within the input but represents the only interpretive signal available beyond the bare firmographics.

Given the absence of disclosed commercial activity, the entity does not present a recognizable revenue model, customer base, or product surface. Any investment-relevant assessment is therefore constrained to the firmographic record: a 2014-vintage, Paris-headquartered, sub-10-employee private entity nominally positioned at the intersection of nanotechnology and healthcare, with no verifiable operating signal in the data set provided.

Name

ETP Nanomedicine

Website

https://etp-nanomedicine.eu

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

ETP Nanomedicine is a Paris-based private entity founded in 2014 with 1-10 employees, focused on applying nanotechnology to healthcare breakthroughs. No products, revenue, funding, team, or customer information are disclosed, and its website is non-functional.

Ownership category

akta.pro rank

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Others

Core offering

ETP Nanomedicine addresses the application of nanotechnology to achieve breakthroughs in healthcare. Operating as the European Technology Platform on Nanomedicine, it functions as an EU-funded initiative framework that advances nanotechnology-based medical innovation across the European research and innovation landscape.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Emerging players

• European Nano Characterization Laboratory (EUSMI / former ECNL): EU-funded nanotechnology infrastructure consortium providing characterization services to academic and industrial users. Comparable as an EU-coordinated nanotech platform, though more infrastructure- and access-oriented than the ETP Nanomedicine agenda-setting remit.

Direct peers

• Starpharma: Australian-listed nanomedicine company focused on dendrimer-based drug delivery and antivirals. Comparable as a commercial-stage nanomedicine developer pursuing healthcare applications, though geographically distant.
• Nanospectra Biosciences: US clinical-stage company developing plasmonic nanoparticle-based selective photothermal therapies. Comparable as a commercial-stage player using engineered nanoparticles to deliver healthcare breakthroughs.
• Cristal Therapeutics: Dutch clinical-stage nanomedicine company developing polymeric nanomedicines for cancer and infectious diseases. European peer operating in the same nanomedicine-for-healthcare category as ETP Nanomedicine's mission.
• Nanobiotix: Paris-headquartered clinical-stage nanomedicine company developing nanoparticle-based cancer therapies. Most direct European nanomedicine peer to ETP Nanomedicine, sharing both the French base and the core nanotech-for-healthcare thesis.
• BlueWillow Biologics: US-based nanotechnology company developing nasal and inhaled nanoemulsion therapeutics for infectious disease and immune modulation. Comparable as a commercial nanomedicine developer in the same healthcare-application thesis.
• European Technology Platform for the Pharma Industry (ETP Pharma): A sibling European Technology Platform focused on pharmaceutical process research. Directly comparable as an EU-coordinated, industry-led research platform under the same ETP framework model.
• Midatech Pharma: UK-based specialty pharma developing nanomedicine-based therapeutics for oncology and rare diseases. Comparable as a European clinical-stage nanomedicine company targeting healthcare breakthroughs through nanoscale drug design and delivery.

Broad incumbents

• Oxford Nanopore Technologies: UK-listed nanotechnology platform commercializing nanopore-based molecular sensing for healthcare and research. Comparable as a large, established commercial entity that took nanotechnology from research platform to scaled product — a reference point for downstream commercialization potential.

Others

• European Commission – Health & Nanotech Programs (Horizon Europe): The EU's central funding and policy apparatus for research programs including nanomedicine and health. Comparable as the funder and agenda-setter for the ETP framework under which ETP Nanomedicine operates.

Market position

Strengths3 records

Weaknesses4 records

Key risks4 records

Key highlights4 records

Customer concentration

• Xx.com/etpnanomedicine
• LinkedInlinkedin.com/company/european-technology-platform-on-nanomedicine-etpn-association-

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ETP Nanomedicine